Blood group |
A |
B |
O |
AB |
P |
NO. |
85 |
28 |
35 |
12 |
Age
>60
<60 |
44(51.7%)
41(48.2%) |
15(53.5%)
13(46.4%) |
19(54.2%)
16(45.7%) |
7(58.3%)
5(41.6%) |
0.24 |
Family history
Yes
No |
20(23.5%)
70(76.4%) |
6(21.4%)
22(78.5%) |
9(25.7%)
26(74.2%) |
3(25.0%)
9(75.0%) |
0.45 |
Menopausal status
Premenopausal
Postmenopausal |
36(42.3%)
49(57.6%) |
13(46.4%)
15(53.5%) |
17(48.5%)
18(51.4%) |
5(41.6%)
7(58.3%) |
0.16 |
Lymph node involvement
Yes
No |
52(61.1%)
33(38.8%) |
17(60.7%)
11(39.2%) |
22(62.8%)
13(37.1%) |
8(66.6%)
2(33.3%) |
0.37 |
Tumor size
>3
<3 |
47(55.2%)
38(44.7%) |
15(53.5%)
13(46.4%) |
18(51.4%)
17(48.5%) |
7(58.3%)
5(41.6%) |
0.30 |
Tumor stage
I&II
III |
42(49.4%)
43(50.5%) |
13(53.5%)
15(46.4%) |
17(48.5%)
18(51.4%) |
5(41.6%)
7(58.3%) |
0.19 |
ER status
Positive
Negative |
45(52.9%)
40(47.0%) |
17(60.7%)
11(39.2%) |
21(60.0%)
14(40.0%) |
7(58.3%)
5(41.6%) |
0.32 |
PR status
Positive
Negative |
62(72.9)
23(27.0%) |
21(75.0%)
7(25.2%) |
28(80.0%)
7(20.0%) |
9(75.0%)
3(25.0%) |
0.28 |
|